We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nutex Health Inc | NASDAQ:NUTX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.647 | 0.6814 | 0.707 | 0 | 09:02:49 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or Other Jurisdiction | (Commission File Number) | (I.R.S. Employer |
(Address of principal executive offices) (zip code)
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbols(s) | Name of each exchange on which registered |
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02. Termination of a Material Definitive Agreement.
On February 8, 2024, Nutex Health, Inc. (the “Company”) and YA II PN, Ltd. (“Yorkville”), terminated the Pre-Paid Advance Agreement dated as of April 11, 2023, as amended (the “PPA”) by the mutual consent of the parties, effective as of February 15, 2024. As previously disclosed, pursuant to the PPA, the Company may request advances of up to $25.0 million each from Yorkville (or such greater amount that parties may mutually agree) (each, a "Pre-Paid Advance”) for a total of up to $100 million, which will be purchased by Yorkville at 90% of the face amount. The initial Pre-Paid Advance requested was $25 million, $15 million of which was paid on April 11, 2023, with the remaining $10 million to be paid upon mutual agreement of the parties. Since the receipt of the initial Pre-Paid Advance, 21.4 million shares of Common Stock have been issued to Yorkville, reducing the principal of the initial Pre-Paid Advance to $8.0 million. Additionally, the Company made Optional Prepayments of $5.2 million in accordance with the PPA, consisting of $4.9 million of principal and $0.3 million attributed to the Payment Premium. The principal of the initial Pre-Paid Advance as of December 31, 2023 was $3.1 million. On January 30, 2024, the Company paid off in full the remaining outstanding balance of the PPA. As of February 15, 2024, the Company’s obligation to request the remaining $10 million Pre-Paid Advance, and Yorkville’s obligation to purchase the remaining $10 million Pre-Paid Advance, has been terminated. At the time of termination, there were no outstanding Pre-Paid Advance, advance notices or shares of Common Stock to be issued under the PPA. In addition, there were no fees due by the Company or Yorkville in connection with the termination of the PPA.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit No. |
| Description of Exhibit |
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document |
Document and Entity Information |
Feb. 15, 2024 |
---|---|
Document and Entity Information [Abstract] | |
Document Type | 8-K |
Document Period End Date | Feb. 15, 2024 |
Entity Registrant Name | NUTEX HEALTH INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-41346 |
Entity Tax Identification Number | 11-3363609 |
Entity Address, Address Line One | 6030 S. Rice Ave |
Entity Address, Adress Line Two | Suite C |
Entity Address, City or Town | Houston |
Entity Address State Or Province | TX |
Entity Address, Postal Zip Code | 77081 |
City Area Code | 713 |
Local Phone Number | 660-0557 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.001 par value |
Trading Symbol | NUTX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001479681 |
Amendment Flag | false |
1 Year Nutex Health Chart |
1 Month Nutex Health Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions